BioLineRx doses first patient in glioblastoma trial with GLIX1 drug

April 28, 2026 7:00 AM

BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS announced the first patient has been dosed in a Phase 1/2a clinical trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found